These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1238 related items for PubMed ID: 26781152

  • 21. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, Bockisch A, Forsting M, Lauenstein T, Antoch G, Stahl A.
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [Abstract] [Full Text] [Related]

  • 22. Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma.
    Berzaczy D, Fueger B, Hoeller C, Haug AR, Staudenherz A, Berzaczy G, Weber M, Mayerhoefer ME.
    Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
    [Abstract] [Full Text] [Related]

  • 23. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC.
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [Abstract] [Full Text] [Related]

  • 24. Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients.
    Bruckmann NM, Sawicki LM, Kirchner J, Martin O, Umutlu L, Herrmann K, Fendler W, Bittner AK, Hoffmann O, Mohrmann S, Dietzel F, Ingenwerth M, Schaarschmidt BM, Li Y, Kowall B, Stang A, Antoch G, Buchbender C.
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2816-2825. PubMed ID: 32333068
    [Abstract] [Full Text] [Related]

  • 25. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
    Grueneisen J, Nagarajah J, Buchbender C, Hoffmann O, Schaarschmidt BM, Poeppel T, Forsting M, Quick HH, Umutlu L, Kinner S.
    Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
    [Abstract] [Full Text] [Related]

  • 26. Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.
    An YS, Kang DK, Jung YS, Han S, Kim TH.
    Eur J Radiol; 2015 Jul; 84(7):1365-70. PubMed ID: 25886700
    [Abstract] [Full Text] [Related]

  • 27. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
    Albano D, Patti C, La Grutta L, Agnello F, Grassedonio E, Mulè A, Cannizzaro G, Ficola U, Lagalla R, Midiri M, Galia M.
    Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
    [Abstract] [Full Text] [Related]

  • 28. [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results.
    Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P, Kraff O, Forsting M, Lauenstein TC, Umutlu L.
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):56-65. PubMed ID: 25223420
    [Abstract] [Full Text] [Related]

  • 29. Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI.
    Beiderwellen K, Gomez B, Buchbender C, Hartung V, Poeppel TD, Nensa F, Kuehl H, Bockisch A, Lauenstein TC.
    Eur J Radiol; 2013 Nov; 82(11):e669-75. PubMed ID: 24011443
    [Abstract] [Full Text] [Related]

  • 30. Speeding up PET/MR for cancer staging of children and young adults.
    Aghighi M, Pisani LJ, Sun Z, Klenk C, Madnawat H, Fineman SL, Advani R, Von Eyben R, Owen D, Quon A, Moseley M, Daldrup-Link HE.
    Eur Radiol; 2016 Dec; 26(12):4239-4248. PubMed ID: 27048532
    [Abstract] [Full Text] [Related]

  • 31. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
    Botsikas D, Bagetakos I, Picarra M, Da Cunha Afonso Barisits AC, Boudabbous S, Montet X, Lam GT, Mainta I, Kalovidouri A, Becker M.
    Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
    [Abstract] [Full Text] [Related]

  • 32. Qualitative and quantitative comparison of PET/CT and PET/MR imaging in clinical practice.
    Al-Nabhani KZ, Syed R, Michopoulou S, Alkalbani J, Afaq A, Panagiotidis E, O'Meara C, Groves A, Ell P, Bomanji J.
    J Nucl Med; 2014 Jan; 55(1):88-94. PubMed ID: 24337608
    [Abstract] [Full Text] [Related]

  • 33. Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.
    Bruckmann NM, Kirchner J, Morawitz J, Umutlu L, Herrmann K, Bittner AK, Hoffmann O, Mohrmann S, Ingenwerth M, Schaarschmidt BM, Li Y, Stang A, Antoch G, Sawicki LM, Buchbender C.
    PLoS One; 2021 Jan; 16(12):e0260804. PubMed ID: 34855886
    [Abstract] [Full Text] [Related]

  • 34. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X, Wu F, Han P.
    Hell J Nucl Med; 2014 Jan; 17(3):177-83. PubMed ID: 25526754
    [Abstract] [Full Text] [Related]

  • 35. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D, Patti C, Lagalla R, Midiri M, Galia M.
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [Abstract] [Full Text] [Related]

  • 36. Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to 18F-FDG PET/CT.
    Zheng D, Liu Y, Liu J, Li K, Lin M, Schmidt H, Xu B, Tian J.
    Cancer Imaging; 2020 Jun 16; 20(1):39. PubMed ID: 32546207
    [Abstract] [Full Text] [Related]

  • 37. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM, Vercher-Conejero JL, Sher AC, Kohan A, Rubbert C, Avril N.
    Q J Nucl Med Mol Imaging; 2013 Dec 16; 57(4):352-66. PubMed ID: 24322792
    [Abstract] [Full Text] [Related]

  • 38. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
    Heusch P, Buchbender C, Beiderwellen K, Nensa F, Hartung-Knemeyer V, Lauenstein TC, Bockisch A, Forsting M, Antoch G, Heusner TA.
    Eur J Radiol; 2013 May 16; 82(5):870-6. PubMed ID: 23394765
    [Abstract] [Full Text] [Related]

  • 39. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y, Yui M, Aoyagi K, Kishida Y, Seki S, Koyama H, Yoshikawa T.
    AJR Am J Roentgenol; 2019 Feb 16; 212(2):311-319. PubMed ID: 30512992
    [Abstract] [Full Text] [Related]

  • 40. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T, Tatsumi M, Onishi H, Nakamoto A, Kim T, Hori M, Sakane M, Hori Y, Morii E, Hatazawa J, Tomiyama N.
    Invest Radiol; 2014 Aug 16; 49(8):524-31. PubMed ID: 24637584
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 62.